Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds.
The Germantown, Md.-based company plans to use its newly-acquired funds to support the commercialization of its implantable continuous glucose monitoring system, Eversense.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics closes $150m public offering appeared first on MassDevice.